Accepted for Publication: November 29, 2012.
Published Online: April 23, 2012. doi:10.1001/archneurol.2011.3354
Author Contributions: Study concept and design: Desikan, Brewer, and Dale. Analysis and interpretation of data: Desikan, McEvoy, Thompson, Holland, Brewer, Aisen, Sperling, and Dale. Drafting of the manuscript: Desikan and Dale. Critical revision of the manuscript for important intellectual content: Desikan, McEvoy, Thompson, Holland, Brewer, Aisen, Sperling, and Dale. Statistical analysis: Desikan, Thompson, and Dale. Obtained funding: Dale. Administrative, technical, and material support: Desikan and Dale. Study supervision: Desikan, McEvoy, Brewer, Sperling, and Dale.
Group Members: A list of the Alzheimer's Disease Neuroimaging Initiative members appears at http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Authorship_List.pdf.
Financial Disclosure: Dr McEvoy's spouse is the chief executive officer of CorTechs Labs. Dr Aisen serves on a scientific advisory board for NeuroPhage as well as serves as a consultant to Elan, Wyeth, Eisai, Bristol-Myers Squibb, Eli Lilly, NeuroPhage, Merck, Roche, Amgen, Abbott Laboratories, Pfizer, Novartis, Bayer, Astellas Pharma, Dainippon, Biomarin, Solvay, Otsuka, Daiichi Sankyo, AstraZeneca, Janssen Pharmaceuticals, Medivation, Theravance, Cardeus, and Anavex. He also receives research support from Pfizer, Baxter International, and the National Institutes of Health (grants 01-AG10483, U01-AG024904, R01-AG030048, and R01-AG16381 from the National Institute on Aging). He has also received stock options from Medivation. Dr Dale is a founder and holds equity in CorTechs Labs and also serves on the company's Scientific Advisory Board. The terms of this arrangement have been reviewed and approved by the University of California–San Diego in accordance with its conflict of interest policies.
Funding/Support: This study was supported by grants R01AG031224, K01AG029218, K02 NS067427, T32 EB005970, P01 AG036694, and K24 AG035007 from the National Institutes of Health and a Young Scholar Award from the Alzheimer's Association San Diego/Imperial Chapter.. Data collection and sharing for this study was funded by the Alzheimer's Disease Neuroimaging Initiative (grant U01 AG024904 from the National Institutes of Health). The Alzheimer's Disease Neuroimaging Initiative (ADNI) is funded by the National Institute on Aging; the National Institute of Biomedical Imaging and Bioengineering; and contributions from Abbott Laboratories, AstraZeneca, Bayer Schering Pharma, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly, Medpace, Merck, Novartis, Pfizer, F. Hoffman-La Roche, Schering-Plough, Synarc, and Wyeth, as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California–San Diego. Alzheimer's Disease Neuroimaging Initiative data are disseminated by the Laboratory for Neuro Imaging at the University of California–Los Angeles. This research was also supported by grants P30 AG010129 and K01 AG030514 from the National Institutes of Health and the Dana Foundation.
Additional Information: Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.ucla.edu/). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this article.